The EPO published patent EP3465335A1 granting intellectual property protection for medium chain fatty acid ester compounds of beta-hydroxybutyrate and butanediol as therapeutic agents. The patent names Eric Verdin, Scott Ulrich, and John Newman as inventors, with applicants including The J. David Gladstone Institutes, The Regents of the University of California, and Ithaca College. The patent covers compositions and methods for using these compounds across eight therapeutic categories spanning oncology, neurology, nephrology, and cardiovascular applications.

Pharmaceutical companies and researchers developing ketone-based therapeutics should review this patent landscape to assess freedom-to-operate considerations. Drug manufacturers working with beta-hydroxybutyrate compounds may need to evaluate licensing requirements or design-around strategies. No compliance deadline applies to this patent publication; entities seeking protection for competing compounds should file before any conflicting applications mature.